Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study.

Onabotulinumtoxin A (onabotA) has shown efficacy in chronic migraine (CM), with good tolerability and a low rate of adverse effects, most of them not severe. The aim of this study is to evaluate tolerability and adverse effects of onabotA in clinical practice and to analyze if there is a relationship between tolerability to treatment administration, adverse effects' (AEs) occurrence and clinical response. We included patients with CM that received treatment with onabotA for the first time.

Survival in Restless Legs Syndrome: An 11-Year Surveillance, Community-Based Population Study.

Background: A growing body of evidence relates restless legs syndrome (RLS) to an increased risk of mortality attributable to both cerebrovascular and cardiovascular events. The aim was to investigate survival in patients with RLS.

Methods: This was an observational, retrospective longitudinal study of a cohort of patients followed up for 11 years.